Subscribe to RSS
DOI: 10.1055/a-1500-8230
Trabeculectomy with OloGen versus Mitomycin C for the Treatment of Silicone Oil-Induced Glaucoma
Trabekulektomie mit OloGen versus Mitomycin-C-Behandlung von silikonölinduziertem Glaukom![](https://www.thieme-connect.de/media/klimo/202209/lookinside/thumbnails/10-1055-a-1500-8230_kl2349-1.jpg)
Abstract
Aim To compare the intraocular pressure-lowering effect and success rate of trabeculectomy with OloGen to that of trabeculectomy with mitomycin C (MMC) in cases of silicone oil-induced glaucoma.
Materials and Methods Forty eyes of forty patients with elevated intraocular pressure (IOP) after vitrectomy and silicone oil injection (followed by silicone oil removal) were assigned to two groups. Group A included 20 cases who underwent trabeculectomy with OloGen, while group B cases contained 20 cases undergoing trabeculectomy with MMC. The follow-up period was 24 months. Patients enrolled had IOP > 21 mmHg despite being on antiglaucoma medications.
Results The mean postoperative IOP reduction was lower in group A than in group B at all follow-up visits, but this difference was not statistically significant (p > 0.05). Moreover, group A and B patients were found to be similar as regards the need for postoperative antiglaucoma medications on all follow-up visits. The Kaplan-Meier survival analysis curves for the two groups revealed slightly higher success rates in group B than in group A. However, these differences were not statistically significant for both qualified success (IOP ≤ 21 mmHg with or without antiglaucoma medications) and complete success (IOP ≤ 21 mmHg without antiglaucoma medications). There was no significant difference in the postoperative complication rate between the two groups.
Conclusion OloGen implant lowers IOP to a similar extent as MMC when combined with trabeculectomy for the treatment of silicone oil-induced glaucoma, and with comparable success rates. The rate of postoperative complications is similar for OloGen implantation and MMC.
Zusammenfassung
Ziel Vergleich des Augeninnendrucksenkungseffekts und der Erfolgsrate der Trabekulektomie mit OloGen mit der Trabekulektomie mit Mitomycin C (MMC) bei silikonölinduziertem Glaukom.
Material und Methoden 40 Augen von 40 Patienten mit erhöhtem Augeninnendruck (IOD) nach Vitrektomie und Silikonölinjektion (gefolgt von Silikonölentfernung) wurden 2 Gruppen zugeordnet. Gruppe A umfasste 20 Fälle, bei denen eine Trabekulektomie mit OloGen durchgeführt wurde, während Gruppe B 20 Fälle enthielt, bei denen eine Trabekulektomie mit MMC durchgeführt wurde. Die Nachbeobachtungszeit betrug 24 Monate. Die eingeschlossenen Patienten hatten einen IOD > 21 mmHg, obwohl sie Medikamente gegen Glaukom erhielten.
Ergebnisse Die mittlere postoperative IOD-Reduktion war in Gruppe A bei allen Nachuntersuchungen niedriger als in Gruppe B, aber dieser Unterschied war statistisch nicht signifikant (p > 0,05). Darüber hinaus wurde festgestellt, dass die Patienten der Gruppen A und B hinsichtlich des Bedarfs an postoperativen Antiglaukommedikamenten bei allen Nachuntersuchungen ähnlich sind. Die Kaplan-Meier-Überlebensanalysekurven für die beiden Gruppen zeigten geringfügig höhere Erfolgsraten, die in Gruppe B im Vergleich zu Gruppe A beobachtet wurden. Diese Unterschiede waren jedoch sowohl für den begrenzten Erfolg (IOD ≤ 21 mmHg mit oder ohne Antiglaukommedikamente) als auch für den vollständigen Erfolg statistisch nicht signifikant (IOD ≤ 21 mmHg ohne Medikamente gegen Glaukom). Es gab keinen signifikanten Unterschied in der postoperativen Komplikationsrate zwischen den beiden Gruppen.
Schlussfolgerung Das OloGen-Implantat zeigt in Kombination mit einer Trabekulektomie zur Behandlung des durch Silikonöl induzierten Glaukoms einen ähnlichen Effekt auf die Senkung des Augeninnendrucks wie MMC mit vergleichbaren Erfolgsraten. Die Rate der postoperativen Komplikationen ist für die OloGen-Implantation und die MMC analog.
Key words
silicone - glaucoma - trabeculectomy - OloGen - mitomycin-C - randomized clinical trial - retina - pharmacologySchlüsselwörter
Silikon - Glaukom - Trabekulektomie - OloGen - Mitomycin C - randomisierte klinische Studie - Glaukom - Retina - PharmakologiePublication History
Received: 07 January 2021
Accepted: 03 May 2021
Article published online:
01 July 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Engelmann K, Becker KA. [Heavy silicone oil endotamponade–a useful alternative to conventional endotamponade]. Klin Monbl Augenheilkd 2009; 226: 699-704
- 2 Romano MR, Angi M, Romano V. et al. Intraocular pressure changes following the use of silicone oil or densiron 68 as endotamponade in pars plana vitrectomy. Clin Ophthalmol 2010; 4: 1391-1396
- 3 Moisseiev J, Barak A, Manaim T. et al. Removal of silicone oil in the management of glaucoma in eyes with emulsified silicone. Retina 1993; 13: 290-295
- 4 Honavar SG, Goyal M, Majji AB. et al. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Ophthalmology 1999; 106: 169-176
- 5 Lucke KH, Foerster MH, Laqua H. Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachments. Am J Ophthalmol 1987; 104: 624-633
- 6 Burk LL, Shields MB, Proia AD. et al. Intraocular pressure following intravitreal silicone oil injection. Ophthalmic Surg 1988; 19: 565-590
- 7 Nguyen QH, Lloyd MA, Heuer DK. et al. Incidence and management of glaucoma after intravitreal silicone oil injection for complicated retinal detachments. Ophthalmology 1992; 99: 1520-1526
- 8 Leaver PK, Grey RH, Garner A. Silicone oil injection in the treatment of massive preretinal retraction. II. Late complications in 93 eyes. Br J Ophthalmol 1979; 63: 361-367
- 9 Hender JD, Budenz DL, Flynn jr. HW. et al. Elevated intraocular pressure and hypotony after silicone oil tamponade for complex retinal detachment: incidence and risk factors. Arch Ophthalmol 1999; 117: 189-195
- 10 Kitazawa Y, Kawase K, Matsushita H. et al. Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol 1991; 109: 1693-1698
- 11 Skuta GL, Beeson CC, Higginbotham EJ. et al. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology 1992; 99: 438-444
- 12 Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology 1991; 98: 317-321
- 13 Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev 2005; (04) CD002897
- 14 Palanca-Capistrano AM, Hall J, Cantor LB. et al. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology 2009; 116: 185-190
- 15 Anand N, Arora S, Clowes M. Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. Br J Ophthalmol 2006; 90: 175-180
- 16 Singh D, Chandra A, Sihota R. et al. Long-term success of mitomycin-augmented trabeculectomy for glaucoma after vitreoretinal surgery with silicone-oil insertion: a prospective case series. Retina 2014; 34: 123-128
- 17 Errico D, Scrimieri FL, Riccardi R. et al. Trabeculectomy Versus Ex-Press Glaucoma Filtration Device in Silicomacrophagocytic Open Angle Glaucoma Secondary to Silicone Oil Emulsification. Middle East Afr J Ophthalmol 2016; 23: 177-182
- 18 Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol 1992; 110: 1049-1050
- 19 Bell RW, Habib NE, OʼBrien C. Long-term results and complications after trabeculectomy with a single pre-operative application of 5-fluorouracil. Eye (Lond) 1997; 11: 663-671
- 20 Gupta S, Chaurasia AK, Chawla R. et al. Long-term outcomes of glaucoma drainage devices for glaucoma post-vitreoretinal surgery with silicone oil insertion: a prospective evaluation. Graefes Arch Clin Exp Ophthalmol 2016; 254: 2449-2454
- 21 Hyung SM, Min JP. Subconjunctival silicone oil drainage through the Molteno implant. Korean J Ophthalmol 1998; 12: 73-75
- 22 Chan CK, Tarasewicz DG, Lin SG. Subconjunctival migration of silicone oil through a Baerveldt pars plana glaucoma implant. Br J Ophthalmol 2005; 89: 240-241
- 23 Chen HS, Ritch R, Krupin T. et al. Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci 2006; 47: 5310-5314
- 24 Hsu WC, Spilker MH, Yannas IV. et al. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci 2000; 41: 2404-2411
- 25 Rosentreter A, Schild AM, Jordan JF. et al. A prospective randomised trial of trabeculectomy using mitomycin C vs. an ologen implant in open angle glaucoma. Eye (Lond) 2010; 24: 1449-1457
- 26 Senthil S, Rao HL, Babu JG. et al. Comparison of outcomes of trabeculectomy with mitomycin C vs. ologen implant in primary glaucoma. Indian J Ophthalmol 2013; 61: 338-342
- 27 Marey HM, Mandour SS, Ellakwa AF. Subscleral trabeculectomy with mitomycin-C versus ologen for treatment of glaucoma. J Ocul Pharmacol Ther 2013; 29: 330-334
- 28 Cillino S, Di Pace F, Cillino G. et al. Biodegradable collagen matrix implant vs. mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial. Eye (Lond) 2011; 25: 1598-1606
- 29 Cillino S, Casuccio A, Di Pace F. et al. Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: five-year follow-up. BMC Ophthalmol 2016; 16: 24
- 30 Elhefney EM, Al-Sharkawy HT, Kishk HM. et al. Safety and efficacy of collagen matrix implantation in infantile glaucoma. Eur J Ophthalmol 2017; 27: 289-294
- 31 Singab AAS, Mohammed OA, Saleem MIH. et al. A Comparative Study: The Use of Collagen Implant versus Mitomycin-C in Combined Trabeculotomy and Trabeculectomy for Treatment of Primary Congenital Glaucoma. J Ophthalmol 2017; 2017: 9241459
- 32 Barr CC, Lai MY, Lean JS. et al. Postoperative intraocular pressure abnormalities in the Silicone Study. Silicone Study Report 4. Ophthalmology 1993; 100: 1629-1635
- 33 Al-Jazzaf AM, Netland PA, Charles S. Incidence and management of elevated intraocular pressure after silicone oil injection. J Glaucoma 2005; 14: 40-46
- 34 Budenz DL, Taba KE, Feuer WJ. et al. Surgical management of secondary glaucoma after pars plana vitrectomy and silicone oil injection for complex retinal detachment. Ophthalmology 2001; 108: 1628-1632
- 35 Souza C, Tran DH, Loman J. et al. Long-term outcomes of Ahmed glaucoma valve implantation in refractory glaucomas. Am J Ophthalmol 2007; 144: 893-900
- 36 Biswas J, Bhende PS, Gopal L. et al. Subconjunctival cysts following silicone oil injection: a clinicopathological study of five cases. Indian J Ophthalmol 1999; 47: 177-180
- 37 Hsu WC, Ritch R, Krupin T. et al. Tissue bioengineering for surgical bleb defects: an animal study. Graefes Arch Clin Exp Ophthalmol 2008; 246: 709-717
- 38 Mohamed TH, Salman AG, Elshinawy RF. Trabeculectomy with Ologen implant versus mitomycin C in congenital glaucoma secondary to Sturge Weber Syndrome. Int J Ophthalmol 2018; 11: 251-255
- 39 Yuan F, Li L, Chen X. et al. Biodegradable 3D-Porous Collagen Matrix (Ologen) Compared with Mitomycin C for Treatment of Primary Open-Angle Glaucoma: Results at 5 Years. J Ophthalmol 2015; 2015: 637537